Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B013 Combined With Paclitaxel in Platinum-resistant Recurrent Ovarian Cancer
NCT06434610Phase 2Recruiting
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of B-013 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Shanghai Cross-linked Pharmaceutical Research and Development. Started Jul 2024; status: recruiting.
02
Drugs
B-013
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06434610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434610.